RARα Luciferase Reporter HEK293 Cell Line
RARα Luciferase Reporter HEK293 Cell Line are engineered HEK293 cells expressing a conditional firefly luciferase reporter under the control of retinoid acid response elements (RARE), and constitutively expressing full length human Retinoic Acid Receptor alpha (RARα, NM_0.00964). This cell line is functionally validated to respond to all-trans retinoic acid (ATRA) stimulation.
Figure 1: Activation of retinoid acid-dependent luciferase reporter in the RARα/RARα Luciferase Reporter HEK293 Cell Line.
Interested in screening and profiling inhibitors or activators of Retinoic Acid Receptor alpha without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
This product has been cited 5 times.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Media Required for Cell Culture
Name | Ordering Information |
Thaw Medium 6 | BPS Bioscience #60183 |
Growth Medium 6A | BPS Bioscience #79542 |
Materials Required for Cellular Assay
Name | Ordering Information |
ATRA | Sigma #R2625 |
Assay Medium 6A | BPS Bioscience #82211 |
96-well tissue culture treated white clear-bottom assay plate | Corning #3610 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
RAR (Retinoic Acid Receptor) belongs to a family of nuclear receptors and has three subtypes: RARa, RARb, and RARg. RAR heterodimerizes with RXR (Retinoid X Receptor) and acts as a transcription factor that regulates the growth and differentiation of both normal and malignant cells. When RAR binds to its ligands, all-trans retinoic acid (ATRA) or 9-cis retinoic acid, the RAR/ RXR heterodimer binds to the retinoic acid response elements in the promoter region of target genes. This recruits coactivator proteins, leading to transcription and expression of the downstream target genes. Retinoic acid (a derivative of Vitamin A) signaling plays critical roles in embryonic and immune system development. Mutations in RARα can lead to Acute Promyelocytic Leukemia (APL), characterized by the accumulation of progenitor cells from the blood lineage (promyelocytes), and other cancer types. Use of RA may prove beneficial in cancer therapy.
2. Allenby, G, et al. Proc. Natl. Acad. Sci. USA (1993) 90(1): 30-34.